Licensing · MENA · Announced 27 Jul 2026
Idorsia → Jamjoom Pharma
Licensing deal between Idorsia (Switzerland) and Jamjoom Pharma (Saudi Arabia), covering QUVIVIQ®, announced 27 Jul 2026.
Parties: Idorsia ltd (Switzerland) → JAMJOOM PHARMACEUTICALS (Saudi Arabia)
- Deal type
- Licensing
- Value
- See terms
- Territory
- Saudi Arabia + the Levant
- Therapeutic area
- CNS / Neurology
- Asset
- QUVIVIQ® (daridorexant) — dual orexin receptor antagonist for insomnia
- Announced
- 27 Jul 2026
Our analysis
Why this matters
Jamjoom moves up into branded, patented innovation. QUVIVIQ isn't a biosimilar or a generic; it's a first-in-class, on-patent branded CNS drug , and a novel mechanism (orexin antagonism — the modern, non-sedative approach to insomnia that avoids the dependence profile of older hypnotics).
For Jamjoom, whose tracker history is anchored in biosimilars (Bio-Thera), complex generics and the Pfizer plant acquisition, this is a step up the value chain into in-licensing innovative, differentiated therapies — the higher-margin, harder-to-source end of the market. It also deepens a genuine CNS franchise rather than adding a one-off.
The full analysis is free to read with a work email on this page.
Source: GCC business news